Drug Trial Radar · NCT02091141
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Apr 14, 2014
Primary completion
May 24, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 19, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.
Conditions
- Neoplasms
- Solid Tumors
- Biliary Cancer
- Salivary Cancer
- Bladder Cancer
Interventions
TrastuzumabDrug
Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
PertuzumabDrug
Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
ErlotinibDrug
Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
VemurafenibDrug
Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
CobimetinibDrug
Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
VismodegibDrug
Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
AlectinibDrug
Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
AtezolizumabDrug
Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the InvestigatorTime frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)
- Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)Time frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
Western Regional Medical Center at Cancer Treatment Centers of America
Goodyear, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Highlands Oncology Group
Springdale, Arkansas
Science 37, Inc
Culver City, California
City of Hope Comprehensive Cancer Center
Duarte, California
Moores UCSD Cancer Center; Dept Clinical Trials Office
La Jolla, California
Eisenhower Medical Center
Rancho Mirage, California
Stanford Comprehensive Cancer Center
Stanford, California
Kaiser Permanente - Vallejo
Vallejo, California
University of Colorado
Aurora, Colorado
SCRI Florida Cancer Specialists South
Fort Myers, Florida
Mayo Clinic
Jacksonville, Florida
Florida Hospital Cancer Inst; Memorial System Onc Clin Rsch
Orlando, Florida
Florida Cancer Specialist, North Region
St. Petersburg, Florida
Florida Cancer Specialists, Research Department
West Palm Beach, Florida
University Cancer & Blood Center, LLC; Research
Athens, Georgia
Northeast Georgia Medical Center; Oncology Research Dept-5C
Gainesville, Georgia
Southeastern Regional Medical Center, Inc.
Newnan, Georgia
Northwestern University; Robert H. Lurie Comp Can Ctr; Northwestern Medicine Development Inst
Chicago, Illinois
University Of Chicago Medical Center; Section Of Hematology/Oncology
Chicago, Illinois
Midwestern Regional Med Center
Zion, Illinois
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Mayo Foundation
Rochester, Minnesota
Research Medical Center - Antibiotic Research Associates, Inc.
Kansas City, Missouri
Memorial Sloan Kettering - Monmouth
Middletown, New Jersey
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
University of New Mexico Comprehensive Cancer Center - Albuquerque Cedar Street; Drug Shipment
Albuquerque, New Mexico
University of New Mexico Comprehensive Cancer Center - Albuquerque Lang NE; Drug Shipment
Albuquerque, New Mexico
University of New Mexico
Albuquerque, New Mexico
San Juan Oncology Associates
Farmington, New Mexico
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York
Weill Cornell Univ Medical Ctr; Breast Cancer Center
New York, New York
Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Univ No Carolina School of Med; Physicians Office Bldg
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Wake Forest Univ Health Svcs; Internal Medicine
Winston-Salem, North Carolina
Sanford Roger Maris Cancer Center
Fargo, North Dakota
Oncology Hematology Care Inc
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.